ZIM
GYRE icon

Zacks Investment Management’s Gyre Therapeutics GYRE Stock Holding History

Zacks Investment Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,526
Closed -$123K – 541
2018
Q3 		$123K Buy
+1,526
New +$121K ﹤0.01% 499
2017
Q3 		– Sell
-4,209
Closed -$147K – 616
2017
Q2 		$147K Buy
+4,209
New +$151K ﹤0.01% 557

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Zacks Investment Management's GYRE Position: Q4 2018 in Review

Zacks Investment Management sold out of Gyre Therapeutics (GYRE) in Q4 2018, closing a stake of 1,526 shares — an estimated $123K sold.

Zacks Investment Management first reported a position in GYRE in Q2 2017 and held it in 2 quarters. The position peaked at $147K in Q2 2017. 65 funds tracked by Wall St. Rank hold GYRE as of Q4 2018.

  • Zacks Investment Management reported no remaining Gyre Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Zacks Investment Management sold 1,526 Gyre Therapeutics shares in Q4 2018, an estimated $123K.
  • Zacks Investment Management first reported a position in Gyre Therapeutics in Q2 2017 and held it in 2 quarters.
  • Zacks Investment Management's Gyre Therapeutics position peaked at $147K in Q2 2017.
  • 65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2018.

Based on Zacks Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.